

**A LISTING OF THE CLAIMS**

1-27. (Canceled).

28. (Previously Presented) An oligonucleotide, comprising: 5'-AACGTT-3', 8-40 nucleotides in length, wherein each internucleotide linkage has a phosphate backbone modification, wherein the phosphate backbone modification is a phosphorothioate.

29. (Previously Presented) An oligonucleotide, comprising: 5'-AACGTT-3', 8-40 nucleotides in length, and having at least one phosphate backbone modification, wherein the oligonucleotide is linked to a nucleic acid delivery complex.

30. (Canceled).

31. (Previously Presented) The oligonucleotide of claim 29, wherein the oligonucleotide is covalently linked to the nucleic acid delivery complex.

32. (Previously Presented) The oligonucleotide of claim 29, wherein the nucleic acid delivery complex is a cationic lipid.

33. (Previously Presented) The oligonucleotide of claim 29, wherein the nucleic acid delivery complex is a sterol.

34-35. (Canceled).

36. (Previously Presented) A composition comprising the oligonucleotide of claim 28 and a pharmaceutically acceptable carrier.